Please ensure Javascript is enabled for purposes of website accessibility

Novavax Stock Is Up on Deal With SK Bioscience

By Taylor Carmichael – Aug 13, 2020 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is adding to the already-massive production capacity it has lined up for its COVID-19 vaccine candidate.

Novavax (NVAX -3.52%) was up 9.1% in early afternoon trading Thursday after it announced that it had signed a development and supply agreement with SK Bioscience, a subsidiary of SK Group, to produce the antigen component of its COVID-19 vaccine candidate. In addition, both companies signed a letter of intent to make Novavax's vaccine available in South Korea.

Word of this deal comes on the heels of major international supply agreements Novavax signed last week. On Aug. 6, it inked a license agreement with the Serum Institute of India to provide a billion doses of Novavax's COVID-19 vaccine throughout India and other low- and middle-income countries. On Aug. 7, Novavax signed a license agreement with Takeda Pharmaceutical (TAK 1.45%) to provide 250 million doses of the vaccine in Japan.  

bottles of COVID-19 vaccine

Image source: Getty Images

While the size of the SK Bioscience deal was not disclosed, Novavax has already lined up enough manufacturing capacity to produce almost 3 billion doses of its vaccine in 2021. By contrast, consider the new COVID-19 vaccine candidate of Moscow-based Binnopharm, which Russian regulators approved for use this week, despite the fact that it has not yet been tested in a phase 3 clinical trial. Binnopharm has said that it can only produce 1.5 million doses of its vaccine per year.

The announcement that the Russian vaccine candidate had been approved for use in its home market sent COVID-19 vaccine stocks tumbling this week. Novavax dropped from a high of $181 a share on Monday to $112 a share on Wednesday. That sell-off was very likely an overreaction, though, given the limited manufacturing capacity available for producing that vaccine, and the lack of trial data that would show whether or not it works well enough to justify its approval.

For the year, Novavax stock remains up by more than 3,200%.

Taylor Carmichael owns shares of Novavax. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.71 (-3.52%) $0.61
Takeda Pharmaceutical Company Stock Quote
Takeda Pharmaceutical Company
TAK
$15.05 (1.45%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.